Moore Capital Management LP Makes New Investment in Omnicell, Inc. $OMCL

Moore Capital Management LP bought a new stake in Omnicell, Inc. (NASDAQ:OMCL) during the 2nd quarter, Holdings Channel reports. The firm bought 87,760 shares of the company’s stock, valued at approximately $3,644,000.

Several other hedge funds have also added to or reduced their stakes in OMCL. Raymond James Financial Inc. bought a new stake in Omnicell in the 2nd quarter valued at $26,000. Versant Capital Management Inc increased its position in Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after buying an additional 294 shares during the period. Clearstead Advisors LLC increased its position in Omnicell by 12,180.0% during the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after buying an additional 1,218 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of Omnicell during the fourth quarter worth $58,000. Finally, Parkside Financial Bank & Trust boosted its position in shares of Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after acquiring an additional 1,264 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Up 6.3%

OMCL stock opened at $35.16 on Tuesday. Omnicell, Inc. has a 52 week low of $29.06 and a 52 week high of $55.00. The business has a 50-day simple moving average of $39.73 and a 200 day simple moving average of $39.32. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.60 billion, a PE ratio of 41.86, a price-to-earnings-growth ratio of 0.83 and a beta of 0.98.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. During the same period in the prior year, the company posted $0.45 earnings per share. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Sell-side analysts anticipate that Omnicell, Inc. will post 1.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wells Fargo & Company lowered their price target on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Piper Sandler restated an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Zacks Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Finally, KeyCorp reiterated an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Omnicell currently has an average rating of “Moderate Buy” and a consensus target price of $57.86.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.